by Michelle Ly | Feb 14, 2011
In previous posts, I discussed the use of cell therapy, specifically the application of allogenic or autologous hematopoietic stem cells (HSCs), as a way to repopulate blood cell lineages to normal levels post-treatment in patients suffering from certain types of...
by Ubaka Ogbogu | Feb 8, 2011
A few weeks ago I blogged about the recent Supreme Court of Canada decision on the constitutional validity of several sections of the Assisted Human Reproduction Act, Canada’s assisted reproduction and embryo research legislation. I am currently preparing a paper for...
by David Grant | Jan 26, 2011
How do newspaper articles portray stem cell tourism? A research team at the University of Alberta recently asked this question, and their results were published last month in the journal Nature. Their conclusions were both surprising, and hopeful. The team, led by...
by Chris Kamel | Jan 24, 2011
Although tumours are typically thought of as a single entity, the cells that make up a tumour are genetically diverse. The traditional view of cancer progression — in which a tumour arises from a single cell after accumulated mutations — suggests that...
by Michelle Ly | Dec 20, 2010
Stem cells were high on the list of hot topics at this year’s American Society of Hematology conference in Orlando, Florida, particularly regarding the uses and effects of stem cells in the treatment of disease. The Ham-Wasserman lecture, named for two past ASH...
by Chris Kamel | Dec 9, 2010
Induced pluripotent stem (iPS) cells are generally created by the expression of a small number of key genes to reprogram adult cells into an undifferentiated, pluripotent state. Because some of the transcription factors used for reprogramming are oncogenes, as well as...
Comments